题名

生命倫理與管制治理的調和：以中國人類胚胎幹細胞研究管制變遷為例

并列篇名

The Harmonizing of Competition, Regulation and Bioethics on Science Governance: The Policy Change of Human Embryonic Stem Cell Research inChina

作者

賴沅暉(Yuan-Hui Lai)

关键词

生命科學 ； 科學治理 ； 幹細胞研究 ； 生命倫理 ； 管制政策 ； China ； science governance ； stem cell research ； bioethics ； regulatory policy

期刊名称

國家與社會

卷期/出版年月

15期（2013 / 12 / 01）

页次

63 - 119

内容语文

繁體中文
中文摘要

在探討為何中國在生命科學領域中，仍然在基礎建設、政策、法律、以及倫理層面上，無法隨科技進展而得以充分發展的議題上，已引發了許多不同的詮釋與論辯。中國的政策制定者在1978年改革開放後，開始接受以建構完備的法律管制與倫理準則作為策略優勢，試圖在生命科學的全球與區域競爭中取得一席之地。對此，本研究主要針對中國對於生命科學研究的管制政策發展與變遷進行分析，並以人類胚胎幹細胞研究為例，探討中國以何種方式邁向新型態的管制政策與建立政策優先性，並將焦點置於中國如何在既有的文化系絡下，建構與西方相容的科學治理體系，探討中國對於生命科學研究管制在概念建構、政策與法律制定，與執行實務上所面臨的挑戰。
英文摘要

Stem cell research is a field that has attracted considerable scientific, financial investment and attention in China. It is also a field surrounded by ethical controversies and policy developments concerning cloning, the moral status of human embryos, sourcing of human embryos for research. However, the fact that the domains of life sciences in China are still seriously underdeveloped in infrastructural, policy, legal and ethical terms has prompted different explanations and debates. Some argue that this lag can be understood as expressing the need for reforms, supporting Chinese efforts to implement a policy of modernization. Others refer to a ”technological imperative” that is deeply ingrained in China's politics and ideology, especially in the areas of population and biomedicine policy. In spite of such biased assumptions, Chinese policy makers were recognized that the discontinuation of political interference with the sciences was essential for their survival, and have adopted a view that regards a sound system of legal regulations and bioethical guidelines as a strategic advantage in the competitions of the global and regional markets of life sciences. Chinese bioethicists find themselves torn between the necessity to re-create a fully-fledged regulatory policy framework that would also accommodate China's culture and aspirations to become global players in the life sciences. The result is a top-down approach in bioethics, embodied newly formulated notions of Chinese society and created on behalf of the people. This research examines efforts to develop systems of science governance in the field of stem cell research and how these relate to the cultural contexts of the country in question. This includes, on the one hand, deliberative efforts to determine what constitutes scientifically sound and ethically appropriate stem cell research, and on the other, regulatory efforts to establish rigorous systems of ethical and stem cell research.
主题分类 社會科學 > 社會科學綜合
社會科學 > 社會學
参考文献
  1. People's Republic of China (PRC) (2006). China issues S & T guidelines. Gov.cn. Chinese Government's Official Website. Available at: http://www.gov.cn/english/2006-02/09/content_183426.htm Accessed 4 January 2008.
  2. (2001).International Encyclopedia of the Social and Behavioral Sciences.
  3. Leggett, K. (2003). “China has tightened genetics regulation – rules ban human cloning. Moves could quiet critics of freewheeling research,” Asian Wall Street Journal. 13 October: A1
  4. UK Stem Cell Initiative (2011). Report and recommendations, Department of Health, London..
  5. Watts. J. (2004). “I don't know how it works,” Guardian. 1 December.
  6. Jia, H. (2006). “China cracks down on malpractice in fertility industry,” SciDev. Net, 10 April. Available at:http://www.scidev.net/dossiers/index.cfm?fuseaction=dossierReadItem&type=1&itemid=2775&language=1&dossier=5&CFID=2592544&CFTOKEN=94836456 . Accessed on 2010 May 4.
  7. China Stem Cell News (2008). Available at: http://www.stemcellschina.com/ . Accessed on 2009 Jul. 23.
  8. Qiu, R. (2007). “China taking the right steps in bioethics,” SciDevNet. 18 May. Available at: http://www.scidev.net/Opinions/index.cfm?fuseaction=readOpinions&itemid=611&language=1 . Accessed on 2009 Apr. 7.
  9. Human Genome Organization (HUGO) (2004). Statement on stem cells. Available at: www.hugo-international.org/PDFs/Statement%20on%20Stem%20Cells%20%202004.pdf Accessed on 2010 May 10.
  10. Xu, G. Minister of Science and Technology, People's Republic of China (2006).“China's science and technology: towards the new era,” Public Lecture. The Shine Dome, Canberra, Australia, 16th February. Available at: http://www.science.org.au/events/16february06.htm .
  11. Ministry of Science and Technology (2007). Regulation on Misconduct in Scientific Research. Available at: http://www.chinaphs.org/bioethics/regula-tions_&_laws.htm#_Toc161968268
  12. Abbott, A.,Cyranoski, D.(2001).China plans 'hybrid' embryonic stem cells.Nature,413,339.
  13. Andrews, L.,Nelkin, D.(2001).Body Bazaar : The Market for Human Tissue in the Biotechnology Age.Crown.
  14. Beck G.K(ed)(2000).The moral status of persons: perspective on bioethics.Amsterdam:Rodopi.
  15. Bionet(2010).,London:Bionet.
  16. Corrigan, O,Liddell, K,McMillan, J,Stewart, A,Wallace, S.(2006).,Cambridge:Cambridge Genetics Knowledge Park.
  17. Department of Trade and Industry(2004).,London:DTI.
  18. Döring, O.(2003).China's struggle for practical regulations in medical ethics.Nature Reviews Genetics,4,233-239.
  19. Drahos, P.,Braithwaite, J.(2002).Information feudalism: who owns the knowledge economy.London:Earthscan.
  20. Englehardt, H.(2002).The Ordination of Bioethicists as Secular Moral Experts.Social Philosophy & Policy,19(2),59-82.
  21. Englehardt, H.(1980).Bioethics in the Peoples's Republic of China.Hastings Center Report,10(2),7-10.
  22. European Commission, DG Research(2004).Survey on opinions from national ethics committees or similar bodies, public debate and national legislation in relation to human embryonic stem cell research and use.Brussels:European Commission.
  23. Fischer, F.(ed.),Miller, G.J.(ed.),Sidney, M.S.(ed.)(2007).Handbook of Public Policy Analysis.Boca Raton:CRC Press.
  24. Fox, R.,Swazey, J.(1984).Medical morality is not bioethics: medical ethics in China and the United States.Perspectives in Biology and Medicine,27,336-60.
  25. Frankena, W.(1973).Ethics.Englewood Cliffs, N.J.:Prentice Hall.
  26. Glasner, P.(Ed.)(2004).Reconfiguring nature: Issues and debates in the new genetics.Aldershot:Ashgate.
  27. Haas, P.M.(ed.)(1992).Introduction: epistemic communities and international policy coordination.International Organization,46(1),1-35.
  28. Hennig, W.(2006).Bioethics in China.European Molecular Biology Organisation,7(9),850-54.
  29. Jasanoff, S.(2005).Designs on nature. Science and democracy in Europe and the United States.Princeton:Princeton University Press.
  30. Jasanoff, S.(ed.)(2004).States of knowledge: the co-production of science and social order.London:Routledge.
  31. Jonsen, A.(1998).The birth of bioethics.New York:Oxford University Press.
  32. Kenney, M.,Han, K.,Tanaka, S.(2002).Report to the World BankReport to the World Bank,未出版
  33. May, C.,Sell, S.(2005).Intellectual property rights: a critical history.Boulder Co:Lynnee Rieener.
  34. Miller, C.(2007).Democratisation, international knowledge institutions and global governance.Governance,20(2),325-57.
  35. Nie, J-B.(2000).The plurality of Chinese and American medical moralities: toward an interpretive cross-cultural bioethics.Kennedy Institute of Ethics Journal,10(3),239-60.
  36. Nie, J-B.(2005).Behind the silence: Chinese voices on abortion.New York:Rowman and Littlefield Publishers Inc..
  37. Nie, J-B.(2001).Informed consent not applicable in China? Intellectual flaws of the 'cultural difference' argument.Formosan Journal of Medical Humanities,2,67-74.
  38. Parry, B.C.(2006).Contested bodies: property models and the commodification of human biological artefacts.Science as Culture,15(2)
  39. Parry, B.C.(2005).Trading the genome: investigating the commodification of bioinformation.New York:Columbia University Press.
  40. Petryna, A(ed.),Lakoff, A(ed.),Kleinman, A(ed.)(2006).Global pharmaceuticals: ethics, markets, practices.Durham:Duke University Press.
  41. Petryna, A.(2005).Ethical Variability: Drug Development and Globalizing Clinical Trials.American Ethnologist,32(2),183-197.
  42. Pickering, A.(1995).The Mangle of Practice: Time, Agency, and Science.Chicago:University of Chicago Press.
  43. Rosenau, J.N.(1995).Governance in the twenty-first centur.Global Governance,1,13-43.
  44. Salter, B.(2007).Global Governance. 13Global Governance. 13,未出版
  45. Salter, B.(2007).Bioethics, politics and the moral economy of human embryonic stem cell science: the case of the European Union's Sixth Framework Programme.New Genetics and Society
  46. Salter, B.(2007).Patenting, morality and human embryonic stem cell science: bioethics and cultural politics in Europe.Regenerative Medicine,2(3),301-11.
  47. Salter, B.(2007).Bioethics and the global moral economy: the cultural politics of human embryonic stem cell science.Science, Technology and Human Values,32(5),1-28.
  48. Salter, B.,Jones, M.(2005).Biobanks and bioethics: the politics of legitimation.Journal of European Public Policy,12(4),710-732.
  49. Salter, B.,Waldby, C.(2007).Global Biopolitics Research Group. Working Paper 24Global Biopolitics Research Group. Working Paper 24,Global Biopolitics Research Group.
  50. Salter, B,Cooper, M,Dickins, A.(2006).China and the global stem cell bioeconomy:an emerging political strategy?.Regenerative Medicine,1(5),671-83.
  51. Sleeboom-Faulkner, M.(2004).Genomics in Asia: Cultural values and bioethical practices.London:Kegan Paul.
  52. Sleeboom-Faulkner, M.(2008).The changing nature of ideology in the life sciences in mainland China: case-studies of human cloning and human embryonic stem cell research (hESR) in medical textbooks (1996-2005).BioSocieties,3(1),21-36.
  53. Southern China National Genome Centre, Bioethics Committee(2004).Ethical guidelines for human embryonic stem cell research.Kennedy Institute of Ethics Journal,14(1),47-54.
  54. Streitfellner, T.(2007).Societal and Cultural Factors in Stem Cell Research: the European Landscape.BIONET Workshop on stem cell research,Shanghai:
  55. Thorsteinsdottir, H. Uyen Quach,Martin, Douglas K,Daar, Abdallah S,Singer, Peter A(2004).Introduction: promoting global health through biotechnology.Nature Biotechnology,22,DC3-DC7.
  56. Tsai, DFC(2001).How should doctors approach patients? A Confucian reflection on personhood.Journal of Medical Ethics,17,44-50.
  57. Tsalikis, J.,Fritzsche, D.J.(1989).Business Ethics: A Literature Review with a Focus on Marketing Ethics.Journal of Business Ethics,8(9),695-743.
  58. UNESCO(2001).World Conference on Science: Science for the 21st Century - A new Commitment,Paris:
  59. Vitell, Scott J.,Singhapakdi, Anusorn,Thomas, James(2001).Consumer Ethics: An Application and Empirical Testing of the Hunt-Vitell Theory of Ethics.Journal of Consumer Marketing,18(2),153-178.
  60. Waldby, C.,Mitchell, R.(2006).Tissue Economies: Gifts, Commodities, and Biovalue in Late Capitalism.Durham:Duke University Press.
  61. Wang, Y.(2003).Chinese ethical views on embryonic stem (ES) cell research.Asian bioethics in the 21st century,Bangkok:
  62. Zhai, X.(2007).Challenges & Governance/Regulatory Responses in China.BIONET Workshop on stem cell research,Shanghai:
  63. Zhai, X.(2004).ABA country report for China 2003.Wubios Journal of Asian and International Bioethics,14,5-10.
  64. Zhang, X.,Bao, Y.(2007).Chinese scientists' attitudes about consent policy related to human genetic databases.Turkiye Klinikleri Journal of Medical Ethics,15,63-68.
  65. 丘祥興(2005)。治療性克隆及人類胚胎管理倫理問題的調查和討論。中國醫學倫理學，18(6)，4-8。
  66. 李天東、陳桂(2006)。人胚胎幹細胞研究的倫理學問題。綿陽師範學院學報，25(3)，98-101。
  67. 李淩松、王莉(2006)。胚胎幹細胞。生命科學，18(4)，318-322。
  68. 沈銘賢、林志新(2005)。胚胎幹細胞研究能否得到倫理辯護。上海交通大學學報（哲學社會科學版），13(6)，5-10。
  69. 汪忠杰、郭繼海、黃濤(2007)。探究基因研究引發的倫理問題。湖北大學學報（哲學社會科學版），34(3)，77-81。
  70. 肖開霖(2003)。「生物世紀」的法學挑戰─羅玉中談克隆技術及其倫理準則法律化問題。中國高新區，2003(3)，27-28。
  71. 邱仁宗、翟曉梅(2008)。在國際背景下我國倫理審查的能力建設：理念和實踐。生命倫理學通訊，12，45-49。
  72. 孫元媛(2005)。生命倫理學及其相關公共政策的研究現狀。中國醫學倫理學，18(3)，18-21。
  73. 曹永福、王雲嶺、楊同衛、鄭林娟、沈秀芹(2004)。我國「醫學倫理委員會」的成立背景、功能和建設建議。中國醫學倫理學，17(5)，31+46。
print cancel